Clinical trials: Outpatient
Heart Failure, Congestive, Myocardial Infarction
IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting
The purpose of this study is to characterize current management of patients with either heart failure or prior myocardial infarction and left ventricular dysfunction and to assess the effect of education, specific clinical…
- Conditions
- Heart Failure, Congestive, Myocardial Infarction, Ventricular Dysfunction, Left
- Trial name
- IMPROVE-HF (NCT00303979)
- Where
- 144 sites in United States
- Volunteers
- 34,810 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Depressive Disorder
A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression
The primary objective is to evaluate the safety and tolerability of abrupt discontinuation of saredutant over 1 week in outpatients with depression who completed 8 weeks of treatment with saredutant 100 mg once daily.
- Trial name
- NCT00429260
- Testing
- Saredutant
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Sanofi
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.
Depressive Disorder, Major
A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain
To determine the efficacy of Duloxetine vs. placebo on pain as determined by change in the Brief Pain Inventory (BPI) from baseline over 8 weeks of treatment
- Trial name
- NCT00191919
- Testing
- Duloxetine Hydrochloride
- Where
- 38 sites in Belgium, Czechia and 4 more
- Volunteers
- 310 people
- Sponsor
- Eli Lilly and Company
Insomnia
An Exploratory Study of NBI-34060 Capsules and Next Day Functioning
NBI-34060 is an investigational (research) medication being studied in people with insomnia. The current study is designed to evaluate how people, who experience a nighttime awakening with difficulty returning to sleep, feel…
- Trial name
- NCT00525941
- Testing
- NBI-34060
- Where
- 4 sites in United States
- Sponsor
- Neurocrine Biosciences
Primary Insomnia, Secondary Insomnia
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
The purpose of this study is to compare an investigational drug (LY2624803) with placebo and with zolpidem in the treatment of outpatients with chronic insomnia.
- Trial name
- SLUMBER (NCT00784875)
- Testing
- LY2624803, zolpidem
- Where
- 49 sites in United States
- Volunteers
- 643 people
- Sponsor
- Eli Lilly and Company
Heart Failure
Monitoring Outpatient Blood VolumE in Heart Failure
In patients discharged following heart failure treatment, the consistency of blood volume status and components over time is unknown.
- Trial name
- MOVE-HF (NCT04660396)
- Testing
- BVA-100
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Daxor Corporation
Epilepsy
A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870
Despite availability of several antiepileptic drugs (AEDs), in one-third of patients, epilepsy remains uncontrolled with AEDs. There is a need to develop new approaches to improve the existing medications to relieve patients'…
- Trial name
- NCT04241965
- Testing
- OPC-214870
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00669110
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Fibromyalgia Syndrome
Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran
Evaluation of the antinociceptive effect of 7 weeks of treatment with milnacipran, compared to placebo, in fibromyalgia out-patients
- Trial name
- NCT00757679
- Testing
- Milnacipran
- Where
- Switzerland
- Volunteers
- 153 people
- Sponsor
- Pierre Fabre Medicament
Covid19
Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19
TB006, a monoclonal antibody, is an anti-inflammatory and anti-fibrotic agent that reduces the severity of underlying diseases in COVID-19 patients.
- Trial name
- NCT04801056
- Testing
- TB006
- Sponsor
- TrueBinding, Inc.
Diabetes Mellitus, Type 2
A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.
The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is non-inferior compared to the standard weight-based…
- Trial name
- NCT00437489
- Testing
- Inhaled Human Insulin (Exubera)
- Where
- 9 sites in Hong Kong, Pakistan and 2 more
- Volunteers
- 49 people
- Sponsor
- Pfizer
Covid19
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19
This is a randomized, placebo-controlled study to assess the safety, PK profile, and efficacy of COVI-AMG in subjects with COVID-19.
- Trial name
- NCT04584697
- Testing
- COVI-AMG
- Sponsor
- Sorrento Therapeutics, Inc.
Covid 19, Influenza
Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza
2. Participants will: Take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses. Visit the clinic on the 7th day of treatment for a check-up and safety tests.
- Trial name
- NCT06817096
- Volunteers
- 340 people
- Sponsor
- Azidus Brasil
Covid19
VIR-7831 for the Early Treatment of COVID-19 in Outpatients
This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.
- Trial name
- COMET-ICE (NCT04545060)
- Testing
- VIR-7831 (sotrovimab)
- Where
- 91 sites in United States, Austria and 5 more
- Volunteers
- 1,057 people
- Sponsor
- Vir Biotechnology, Inc.
Parkinson's Disease (PD)
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of 4 weeks of continuous infusion with ABBV-951 in adult subjects with Parkinson's Disease (PD).
- Trial name
- NCT03374917
- Testing
- ABBV-951
- Where
- 12 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbbVie
Depression, Anxiety
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial.
- Trial name
- UHS (NCT01632267)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Assurex Health Inc.
Pulmonary Disease, Chronic Obstructive
Danish Quality Assurance Project on Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD) in Outpatient Lung Clinics
Danish Quality Assurance Project on Diagnosis and Treatment of COPD in Outpatient Lung Clinics
- Trial name
- NCT00268866
- Testing
- Education
- Volunteers
- 1,820 people
- Sponsor
- Boehringer Ingelheim
COVID-19
Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection
This is prospective double-blind study in the United States is designed to investigate the efficacy and safety of a single dose of COVI-DROPS or matched placebo in outpatient adults with mild symptoms associated with COVID-19 and…
- Trial name
- US (NCT05074394)
- Testing
- COVI-DROPS
- Sponsor
- Sorrento Therapeutics, Inc.
Respiratory Syncytial Virus Infections
Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age
The purpose of this study is to collect clinical outcome and nasal viral load information.
- Trial name
- NCT01754428
- Where
- 15 sites in United States
- Volunteers
- 2,432 people
- Sponsor
- Gilead Sciences